705 related articles for article (PubMed ID: 15710984)
1. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease.
Costa F; Mumolo MG; Ceccarelli L; Bellini M; Romano MR; Sterpi C; Ricchiuti A; Marchi S; Bottai M
Gut; 2005 Mar; 54(3):364-8. PubMed ID: 15710984
[TBL] [Abstract][Full Text] [Related]
2. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
[TBL] [Abstract][Full Text] [Related]
3. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
[TBL] [Abstract][Full Text] [Related]
4. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
[TBL] [Abstract][Full Text] [Related]
5. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
[TBL] [Abstract][Full Text] [Related]
7. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
[TBL] [Abstract][Full Text] [Related]
8. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
[TBL] [Abstract][Full Text] [Related]
9. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
[TBL] [Abstract][Full Text] [Related]
10. Fecal calprotectin: a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy.
Koulaouzidis A; Douglas S; Rogers MA; Arnott ID; Plevris JN
Scand J Gastroenterol; 2011 May; 46(5):561-6. PubMed ID: 21269246
[TBL] [Abstract][Full Text] [Related]
11. Faecal calprotectin in the assessment of Crohn's disease activity.
Gaya DR; Lyon TD; Duncan A; Neilly JB; Han S; Howell J; Liddell C; Stanley AJ; Morris AJ; Mackenzie JF
QJM; 2005 Jun; 98(6):435-41. PubMed ID: 15879440
[TBL] [Abstract][Full Text] [Related]
12. Can calprotectin predict relapse risk in inflammatory bowel disease?
D'Incà R; Dal Pont E; Di Leo V; Benazzato L; Martinato M; Lamboglia F; Oliva L; Sturniolo GC
Am J Gastroenterol; 2008 Aug; 103(8):2007-14. PubMed ID: 18802997
[TBL] [Abstract][Full Text] [Related]
13. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease.
Naismith GD; Smith LA; Barry SJ; Munro JI; Laird S; Rankin K; Morris AJ; Winter JW; Gaya DR
Aliment Pharmacol Ther; 2013 Mar; 37(6):613-21. PubMed ID: 23347334
[TBL] [Abstract][Full Text] [Related]
14. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12.
Whitehead SJ; Ford C; Gama RM; Ali A; McKaig B; Waldron JL; Steed H; Brookes MJ
J Clin Pathol; 2017 Dec; 70(12):1049-1056. PubMed ID: 28735301
[TBL] [Abstract][Full Text] [Related]
15. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
[TBL] [Abstract][Full Text] [Related]
17. Faecal calprotectin: a new marker for Crohn's disease?
Wassell J; Dolwani S; Metzner M; Losty H; Hawthorne A
Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438
[TBL] [Abstract][Full Text] [Related]
18. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy.
Sipponen T; Haapamäki J; Savilahti E; Alfthan H; Hämäläinen E; Rautiainen H; Koskenpato J; Nuutinen H; Färkkilä M
Scand J Gastroenterol; 2012 Jul; 47(7):778-84. PubMed ID: 22519419
[TBL] [Abstract][Full Text] [Related]
19. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
[TBL] [Abstract][Full Text] [Related]
20. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]